AHP announces its investment in Prolerity Clinical Research (“Prolerity”), a clinical research site management network. As a cornerstone to the formation of Prolerity, AHP has made a majority investment in Tandem Clinical Research, LLC (“Tandem”), which operates 11 research sites across Louisiana, Florida, New Jersey, and New York. Prolerity is focused on expanding into a leading site management network with a therapeutic breadth across complex and challenging phase I-III studies, including NASH/NAFLD, cardiology, CNS, gastroenterology, metabolic diseases, and other therapeutic areas. Tandem, headquartered in New Orleans, has become widely known for operating best-in-class research sites for NASH/NAFLD and neurodegenerative studies.
Read the full article: AHP Announces Formation of Prolerity Clinical Research and Investment in Tandem Clinical Research //
Source: https://www.prnewswire.com/news-releases/ahp-announces-formation-of-prolerity-clinical-research-and-investment-in-tandem-clinical-research-302066546.html